20170131-三星证券-Samsung_Healthcare_Weekly_14页_938kb

报告摘要

Sector Update Summary

Core Content Overview

This document provides an analysis of the global healthcare and related sectors, with a specific focus on the Korean pharmaceutical and biotech industry, as well as medical devices and healthcare equipment and services. It includes performance metrics, forward P/E ratios, P/B ratios, and market share data for various indices and companies. The report is authored by Samsung Securities analysts and includes insights on stock price movements and valuation metrics.

Key Analysts and Contact Information

Brian Lee - Team Head (Pharm/Biotech)
Email: brian79.lee@samsung.com
Phone: 822 2020 7177
SunYoung Yoon - Analyst (Pharm/Biotech)
Email: sy85.yoon@samsung.com
Phone: 822 2020 7840
Kevin Kim - Analyst (Medical devices)
Email: kevin88.kim@samsung.com
Phone: 822 2020 7178
Wonyong Park - Research Associate
Email: wkrw.park@samsung.com
Phone: 822 2020 7847

Global Healthcare Indices

Country	Index	Forward P/E (x)	Portion of market cap (%)	1-w (%)	1-m (%)	3-m (%)	ytd (%)
Korea	KRX Health Care	34.1	4.9	(3.1)	(3.6)	(10.1)	(6.7)
Korea	Kospi Medical Supplies	42.9	2.1	(1.5)	(2.5)	(5.4)	(4.1)
Korea	Kosdaq Pharmaceuticals	27.6	2.2	(2.5)	(2.7)	(8.8)	(7.0)
Korea	Kosdaq Medical and Precision Machines	17.8	0.5	(2.3)	(0.2)	(6.3)	(2.8)
US	S&P 500 Healthcare	14.7	8.0	(0.2)	1.2	2.9	1.2
US	S&P 500 Pharma/Biotech	13.8	4.9	(0.5)	(0.5)	0.8	(0.5)
US	Nasdaq Biotechnology	33.2	2.4	0.4	3.5	5.3	3.5
US	S&P 500 Healthcare equipment and services	16.3	3.2	0.5	3.9	6.4	3.9
Europe	MSCI Europe Healthcare	15.3	11.1	1.5	(0.0)	5.4	(0.0)
Europe	MSCI Europe Pharm/Bio	14.8	9.6	1.6	(0.1)	5.4	(0.1)
Europe	MSCI Europe Healthcare Equipment and Services	21.1	1.5	0.4	0.4	5.3	0.4
Japan	MSCI Japan Healthcare	24.7	7.0	1.6	(1.3)	0.6	(1.3)
Japan	MSCI Japan Pharm/Bio	23.9	5.1	0.9	(1.8)	(0.5)	(1.8)
Japan	Topix Pharma	23.5	4.6	0.1	(2.5)	(1.2)	(2.5)
Japan	MSCI Japan Healthcare Equipment and Services	26.5	2.0	3.4	(0.2)	3.3	(0.2)
China	MSCI China Healthcare	17.5	1.6	(1.1)	6.8	1.3	6.8
India	MSCI India Healthcare	24.0	7.6	0.9	1.3	(10.0)	1.3

Korean Healthcare Sector Performance

Pharmaceutical Holdings

Hanmi Science: 1-w: 0.0, 1-m: (31.6), 3-m: (5.4), ytd: (59.6), From peak: (36.7)
Green Cross Holdings: 1-w: (10.4), 1-m: (8.3), 3-m: (11.0), ytd: (9.9), From peak: (36.7)
Donga Socio Holdings: 1-w: (12.7), 1-m: (14.8), 3-m: (20.1), ytd: (21.1), From peak: (35.7)
Daewooong: 1-w: (4.9), 1-m: (5.3), 3-m: (11.7), ytd: (5.3), From peak: (32.1)
JW Holdings: 1-w: (3.1), 1-m: (9.9), 3-m: (44.1), ytd: (14.1), From peak: (56.4)
Chongkundang Holdings: 1-w: (6.5), 1-m: (16.9), 3-m: (14.2), ytd: (16.4), From peak: (34.9)

Pharmaceuticals

Hanmi Pharm: 1-w: (2.4), 1-m: (13.1), 3-m: (29.1), ytd: (6.4), From peak: (54.4)
Yuhan: 1-w: (4.0), 1-m: (5.5), 3-m: (20.8), ytd: (4.0), From peak: (39.2)
Green Cross: 1-w: (4.8), 1-m: (10.6), 3-m: (4.5), ytd: (11.5), From peak: (25.7)
SK Chemicals: 1-w: (6.0), 1-m: (11.0), 3-m: (4.0), ytd: (12.8), From peak: (16.7)
Young Jin Pharm: 1-w: (9.1), 1-m: (13.2), 3-m: (20.5), ytd: (15.2), From peak: (43.5)
Bukwang Pharmaceutical: 1-w: (4.9), 1-m: (14.3), 3-m: 2.1, ytd: (15.5), From peak: (28.1)
Chong Kun Dang: 1-w: (4.6), 1-m: (8.6), 3-m: (14.2), ytd: (16.4), From peak: (34.9)
JW Pharmaceutical: 1-w: (6.8), 1-m: (11.1), 3-m: (22.2), ytd: (17.3), From peak: (53.6)
Daewoong: 1-w: (6.1), 1-m: (2.3), 3-m: (4.5), ytd: (1.3), From peak: (25.8)
Donga ST: 1-w: (5.5), 1-m: (1.1), 3-m: (7.1), ytd: (15.7), From peak: (26.5)
Boryung Pharm: 1-w: (4.5), 1-m: (16.6), 3-m: (11.5), ytd: (18.2), From peak: (28.4)
Samjin Pharm: 1-w: (0.3), 1-m: (9.5), 3-m: (1.5), ytd: (3.5), From peak: (13.1)
Kwang Dong Pharm: 1-w: (3.9), 1-m: (4.3), 3-m: (1.7), ytd: (14.6), From peak: (43.5)
Daewon Pharmaceutical: 1-w: (7.7), 1-m: (1.0), 3-m: (14.1), ytd: (3.1), From peak: (40.7)
Huons: 1-w: (4.6), 1-m: (8.4), 3-m: (6.4), ytd: (15.8), From peak: (39.6)
Whan In Pharm: 1-w: (2.3), 1-m: (5.4), 3-m: (0.7), ytd: (5.4), From peak: (11.2)
ST Pharm: 1-w: 3.0, 1-m: (1.0), 3-m: (0.6), ytd: (7.0), From peak: (23.2)
Kolon Life Science: 1-w: (3.9), 1-m: (7.2), 3-m: (24.0), ytd: (8.4), From peak: (35.8)
Kyongbo Pharmaceutical: 1-w: (4.1), 1-m: (5.5), 3-m: (7.1), ytd: (6.8), From peak: (28.0)
Daebongs: 1-w: (7.2), 1-m: (3.5), 3-m: (4.8), ytd: (0.8), From peak: (21.9)
CKD Bio: 1-w: (1.4), 1-m: (7.3), 3-m: (7.9), ytd: (8.3), From peak: (23.7)
Hwail Pharm: 1-w: (2.8), 1-m: (9.6), 3-m: (2.5), ytd: (9.6), From peak: (27.8)
Estech Pharma: 1-w: (7.7), 1-m: (14.5), 3-m: (30.6), ytd: (16.9), From peak: (49.9)

APIs

ST Pharm: 1-w: 3.0, 1-m: (1.0), 3-m: (0.6), ytd: (7.0), From peak: (23.2)
Kolon Life Science: 1-w: (3.9), 1-m: (7.2), 3-m: (24.0), ytd: (8.4), From peak: (35.8)
Kyongbo Pharmaceutical: 1-w: (4.1), 1-m: (5.5), 3-m: (7.1), ytd: (6.8), From peak: (28.0)
Daebongs: 1-w: (7.2), 1-m: (3.5), 3-m: (4.8), ytd: (0.8), From peak: (21.9)
CKD Bio: 1-w: (1.4), 1-m: (7.3), 3-m: (7.9), ytd: (8.3), From peak: (23.7)
Hwail Pharm: 1-w: (2.8), 1-m: (9.6), 3-m: (2.5), ytd: (9.6), From peak: (27.8)
Estech Pharma: 1-w: (7.7), 1-m: (14.5), 3-m: (30.6), ytd: (16.9), From peak: (49.9)

Industrial-use enzymes

Amicogen: 1-w: (2.5), 1-m: (4.4), 3-m: (17.0), ytd: (9.3), From peak: (38.0)
GenoFocus: 1-w: (8.0), 1-m: (9.5), 3-m: (12.1), ytd: (11.8), From peak: (32.3)

Biosimilars

Celltrion: 1-w: (0.3), 1-m: (0.9), 3-m: (0.3), ytd: (6.7), From peak: (12.0)
Samsung Biologics: 1-w: 5.6, 1-m: 11.8, 3-m: 0.0, ytd: 6.6, From peak: (8.3)
Binex: 1-w: (0.9), 1-m: (6.6), 3-m: (2.6), ytd: (5.4), From peak: (27.1)
Alteogen: 1-w: (2.8), 1-m: (9.6), 3-m: (15.1), ytd: (13.3), From peak: (40.7)
ISU Abaxis: 1-w: (5.1), 1-m: (11.4), 3-m: (17.2), ytd: (38.2), From peak: (38.2)

Stem cell therapy

Chabiotech: 1-w: (1.7), 1-m: (3.3), 3-m: (18.1), ytd: (7.1), From peak: (30.4)
Medipost: 1-w: (6.9), 1-m: (0.6), 3-m: (17.3), ytd: (3.1), From peak: (37.2)
Pharmicell: 1-w: (0.7), 1-m: (5.4), 3-m: (2.5), ytd: (6.8), From peak: (24.6)
Tego Science: 1-w: (1.1), 1-m: (3.5), 3-m: (15.1), ytd: (8.4), From peak: (31.6)
Corestem: 1-w: (1.0), 1-m: (2.0), 3-m: (30.6), ytd: (16.9), From peak: (38.7)

Immune cell therapy

Green Cross Cell: 1-w: (8.7), 1-m: (0.9), 3-m: (13.6), ytd: (5.1), From peak: (27.3)
Green Cross Lab Cell: 1-w: (4.6), 1-m: (7.7), 3-m: (16.8), ytd: (8.3), From peak: (15.6)
JW Shinyak: 1-w: (2.2), 1-m: (1.0), 3-m: (3.1), ytd: (15.6), From peak: (42.5)

Molecular diagnostics

Seegene: 1-w: (0.9), 1-m: (2.5), 3-m: (14.7), ytd: (5.3), From peak: (14.7)
Panagene: 1-w: (2.5), 1-m: (3.6), 3-m: (5.5), ytd: (4.4), From peak: (21.5)
Bioneer: 1-w: (2.3), 1-m: (4.9), 3-m: (9.2), ytd: (15.1), From peak: (42.8)
MG MED: 1-w: (8.0), 1-m: (7.4), 3-m: (6.4), ytd: (12.9), From peak: (12.9)

Market Cap and Share Price Insights

Korea Healthcare: Accounts for 5.0% of total trading volume, down by 4.5% from the previous month.
Korea Pharmaceuticals: Market cap data is provided for each company, with share prices ranging from 5,630 to 100,200 KRW.
Global Healthcare Firms: Includes data on market cap, share price, P/E, and P/B ratios for companies like Celltrion, Samsung Biologics, and others.

Summary of Key Insights

The global healthcare sector shows mixed performance across regions, with varying forward P/E and P/B ratios.
In Korea, the pharmaceutical and biotech sector is a significant part of the market, with notable fluctuations in share prices.
Companies like Samsung Biologics and Celltrion are highlighted for their performance in biosimilars and other therapeutic areas.
The medical devices sector in Korea also shows a range of performances, with some companies experiencing positive growth and others facing declines.

This summary provides an overview of the key metrics and performance trends across the global and Korean healthcare sectors, focusing on pharmaceuticals, biotechnology, and medical devices.

展开完整摘要